• Co-founder, chair of the Board, CEO and holder of an executive leadership role overseeing all research and non-research functions, Rallybio LLC.
• Senior advisor to New Leaf Venture Partners, LLC.
• Member of the board of 5:01 Acquisition Corporation.
• Member of the board and chair of the Science and Technology Committee of Charles River Laboratories International, Inc.

• President of Global Research and Development at AstraZeneca plc., 2010-2013.
• President and senior vice president within Research and Development, and other roles, Pfizer, Inc., 1995-2010.
• Visiting professor at the Department of Pharmacy at King’s College, London, 1998-2006 and at the Department of Biomedical Sciences at the University of Lincoln, 1998-2014.

• Considered independent under the Danish Recommendations on Corporate Governance.
• Member of the Board of Directors since March 2018. Most recently elected in 2021 for a term of one year.
• Chair of the Research & Development Committee since March 2018.
• Member of the Remuneration Committee since March 2021.

• Global corporate leadership
• Healthcare and pharma industry
• Medicine & science
• Technology
• Business development, M&A and external innovation sourcing
• Human capital management

• 1984: Doctorate/PhD, University of Edinburgh, UK.
• 1979: BSc (First Class Honours) in Microbiology, Heriot-Watt University, Edinburgh, UK.

US national, born 1956. Male.